外周血液中循环肿瘤细胞和循环游离DNA检测在乳腺癌患者中的应用

目的 探究外周血液中循环肿瘤细胞(CTCs)和循环游离DNA(cfDNA)检测在乳腺癌患者中的应用效果.方法 收集本院2018-02-2019-02收治的94例乳腺癌患者、48例乳腺良性疾病患者及56例健康体检者外周血液标本,采用基于尺寸的高通量微流控芯片捕获CTCs、基于Alu序列的实时荧光定量PCR检测游离DNA长...

Application of peripheral blood circulating tumor cells and circulating-free DNA in diagnosis of breast cancer

Objective To study the applied value of peripheral blood circulating tumor cells(CTCs)and circulating-free DNA(cfDNA)in diagnosis of breast cancer.Methods From February 2018 to February 2019,peripheral blood samples from 94 breast cancer patients,48 benign breast disease patients and 56 healthy check-ups were obtained.High-throughout micro-fluid chip was applied for detection of CTCs;based on Alu sequence,real time quantitative PCR was used to detect long and short DNA segment(247 bp,115 bp)while the ratio of PCR product based on long and short segment was used to determine the integrity of DNA.The diagnostic value of CTCs and cfDNA was assessed.Results Number of CTCs and Alu 247/115 of cfDNA in breast cancer patients were significantly higher than healthy check-ups and benign breast disease patients(P<0.05);number of CTCs and Alu 247/115 of cfDNA was related to patient’s age,grade,lymphatic metastasis,molecular subtyping,distant metastasis and PR(P<0.05);pathological results were regarded as gold standards,Youden index at maximum point was used as critical value;a control study was conducted among breast cancer patients,benign breast disease patients and healthy check-ups;when cut-off value was 7.68 CTCs/ml,the diagnostic sensitivity and specificity were 80.4%and 96.4%,area under the curve was 0.885(95%CI:0.805~0.965);when cutoff value of Alu 247/115 was 0.431,the diagnostic specificity and sensitivity were 71.4%and 71.7%,area under the curve was 0.727(95%CI:0.608~0.847).Conclusion CTCs and cfDNA can be used as the potential biological indicators for auxiliary diagnosis of breast cancer;CTCs are applicable for detection of tumor cells and cfDNA for DNA segment of tumor.Therefore,CTCs and cfDNA are conductive to analyzing the illness states and taking the auxiliary diagnosis of breast cancer.